Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.8 billion in assets, with a track record of investing and returning capital since 2000.

learn more

Latest News

Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofi’s Dupilumab for Peanut Allergy

October 16, 2017
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced a clinical collaboration with Regeneron and its strategic alliance collaborator Sanofi to…
READ MORE

TransEnterix Announces US 510(k) FDA Clearance for Senhance Surgical Robotic System

October 13, 2017
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced the Company has received FDA 510(k)…
READ MORE

ObsEva SA Announces $60.0 Million Private Placement with Existing and New Investors

October 10, 2017
Geneva, Switzerland and Boston, MA - 10 October, 2017 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions…
READ MORE